Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Trial StartGB-5267Positive

AI Analysis

Summary

Generate Biomedicines and Roswell Park have launched an exclusive clinical trial of GB-5267, an AI-optimized 'armored' CAR T therapy designed to enhance T-cell function in solid tumors. The trial marks the first next-generation cell therapy for ovarian cancer to enter clinical development.

Clinical Trial Data

Outcome Details

First next-generation 'armored' CAR T therapy for ovarian cancer to enter clinical trials

Importance:6/10

Sentiment:

0.60

CAR-T therapyOvarian cancerCell therapyAI-engineeredSolid tumorsClinical trialPartnership

Related Companies

$GBIO

Read the original article

Published by GlobeNewswire Clinical Studies on October 1, 2026 11:00 AM

Read Original